SAMHD1 and acute myeloid leukemia: Inhibition of HSP90 by its small-molecule inhibitors leads to the depletion of various HSP90 client proteins, including multiple oncogenic proteins.36,42,43 Thus, HSP90 is widely recognized as a promising molecular target for anti-cancer therapeutic strategies.44–48 We speculated that targeting HSP90 could be a potential way to downregulate SAMHD1 in AML cells.